© 1995 American Heart Association, Inc.
Articles |
Antithrombotic Effects of Activated Protein C and Protein S in a Rabbit Model of Microarterial Thrombosis
From the Departments of Plastic and Reconstructive Surgery (B.A.), Experimental Research (B.A.), and Clinical Chemistry and Coagulation Research (B.D.), University of Lund, Malmö General Hospital, Malmö, Sweden.
Correspondence to Björn Arnljots, Department of Plastic and Reconstructive Surgery, Malmö General Hospital, S-214 01 Malmö, Sweden.
Abstract The antithrombotic properties of activated protein C (APC) and protein S were investigated in a rabbit model of microarterial thrombosis. The study focused on the ability of intact and thrombin-cleaved bovine protein S to potentiate the biological effects of bovine APC in vivo. Segments of the central arteries of the ears were subjected to arteriotomy, deep-vessel wall trauma, and arteriotomy suture. Five minutes before vascular reperfusion, groups of rabbits were infused with boluses of 0.1 mg/kg bovine APC alone or combined with different doses of intact (0.5, 0.1, or 0.05 mg/kg) or thrombin-cleaved (0.5 mg/kg) protein S. APC in combination with the two higher doses of protein S produced a potent antithrombotic response, as judged by assessment of vessel patency rates, while only the group receiving APC+0.5 mg/kg protein S showed significant reduction of thrombus weights as well. The biological effect depended on the active site in APC, as the antithrombotic effect was lost on pretreatment of APC with the serine protease inhibitor D-phenylalanyl-L-prolyl-L-arginine chloromethylketone. The potentiation of the APC response by protein S depended on the structural integrity of the protein, and cleavage of the thrombin-sensitive region in protein S by thrombin resulted in a loss of biological response. No hemorrhagic side effects were noted by the APC–protein S combination, and the anticoagulant response was mild, even to the highest doses of APC and protein S. The study demonstrates the specificity of the APC–protein S interaction in vivo and shows both the necessity of an active catalytic site in APC and the physiological importance of the APC–protein S interaction. APC appears to be a suitable antithrombotic agent when fully potentiated by its cofactor protein S, as it produces only mild plasma anticoagulation and no hemorrhagic side effects.
Key Words: protein C • protein S • thrombosis • animal model
This article has been cited by other articles:
 |
|
 |
|
  G. Alsfasser, A. L. Warshaw, S. P. Thayer, B. Antoniu, M. Laposata, K. B. Lewandrowski, and C. Fernandez-del Castillo Decreased Inflammation and Improved Survival With Recombinant Human Activated Protein C Treatment in Experimental Acute Pancreatitis Arch Surg, July 1, 2006; 141(7): 670 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Liu, H. Guo, J. H. Griffin, J. A. Fernandez, and B. V. Zlokovic Protein S Confers Neuronal Protection During Ischemic/Hypoxic Injury in Mice Circulation, April 8, 2003; 107(13): 1791 - 1796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A.F. Nicolaes and B. Dahlback Factor V and Thrombotic Disease: Description of a Janus-Faced Protein Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 530 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shibata, S. R. Kumar, A. Amar, J. A. Fernandez, F. Hofman, J. H. Griffin, and B. V. Zlokovic Anti-Inflammatory, Antithrombotic, and Neuroprotective Effects of Activated Protein C in a Murine Model of Focal Ischemic Stroke Circulation, April 3, 2001; 103(13): 1799 - 1805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A.F. Nicolaes and B. Dahlback Factor V and Thrombotic Disease: Description of a Janus-Faced Protein Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 530 - 538. [Abstract] [Full Text] [PDF]
|
|